{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T21:41:26Z","timestamp":1769809286461,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese Medicine Research Project"},{"name":"Futian Healthcare Research Project"},{"name":"Shenzhen Association of Chinese Medicine","award":["(Grant No. 2024140F)"],"award-info":[{"award-number":["(Grant No. 2024140F)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34553-8","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T02:05:39Z","timestamp":1767578739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Caffeic acid phenethyl ester induced apoptosis in chronic myeloid leukemia cells by inhibiting mitochondrial complex I"],"prefix":"10.1038","volume":"16","author":[{"given":"Meng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihua","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhe","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"34553_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/nejm199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl, S. et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164\u2013172. https:\/\/doi.org\/10.1056\/nejm199907153410306 (1999).","journal-title":"N. Engl. J. Med."},{"key":"34553_CR2","doi-asserted-by":"publisher","unstructured":"Senapati, J., Jabbour, E., Kantarjian, H. & Short, N. J. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37, 5\u201317, https:\/\/doi.org\/10.1038\/s41375-022-01736-5(2023).","DOI":"10.1038\/s41375-022-01736-5(2023"},{"key":"34553_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/ajh.27100","volume":"98","author":"FG Haddad","year":"2023","unstructured":"Haddad, F. G. & Short, N. J. Treatment discontinuation in chronic myeloid leukemia: When, how, and why? Am. J. Hematol. 98, 1670\u20131672. https:\/\/doi.org\/10.1002\/ajh.27100 (2023).","journal-title":"Am. J. Hematol."},{"key":"34553_CR4","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.2174\/0929867330666230519105900","volume":"31","author":"J Su","year":"2024","unstructured":"Su, J. et al. Screening and activity evaluation of novel BCR-ABL\/T315I tyrosine kinase inhibitors. Curr. Med. Chem. 31, 2872\u20132894. https:\/\/doi.org\/10.2174\/0929867330666230519105900 (2024).","journal-title":"Curr. Med. Chem."},{"key":"34553_CR5","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.3390\/pharmaceutics15112535","volume":"15","author":"NE Verhagen","year":"2023","unstructured":"Verhagen, N. E., Koenderink, J. B., Blijlevens, N. M., Janssen, J. J. & Russel, F. G. Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia. Pharmaceutics 15, 2535. https:\/\/doi.org\/10.3390\/pharmaceutics15112535 (2023).","journal-title":"Pharmaceutics"},{"key":"34553_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini, S. et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood J. Am. Soc. Hematol. 118, 1208\u20131215. https:\/\/doi.org\/10.1182\/blood-2010-12-326405 (2011).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"34553_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.05.052","volume":"31","author":"HR Lai","year":"2023","unstructured":"Lai, H. R., Wu, Q. M., Yang, Y. Z. & Li, J. Recent advance of newly therapy for chronic myeloid leukemia with BCR-ABL T315I mutation\u2013review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 31, 1579\u20131583. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2023.05.052 (2023).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"34553_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1590\/s1679-45082011rb2022","volume":"10","author":"VR Minciacchi","year":"2021","unstructured":"Minciacchi, V. R., Kumar, R. & Krause, D. S. Chronic myeloid leukemia: a model disease of the past, present and future. Cells 10, 117. https:\/\/doi.org\/10.1590\/s1679-45082011rb2022 (2021).","journal-title":"Cells"},{"key":"34553_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ajh.27355","volume":"99","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian, H. M. et al. Ponatinib-review of historical development, current status, and future research. Am. J. Hematol. 99, 1576\u20131585. https:\/\/doi.org\/10.1002\/ajh.27355 (2024).","journal-title":"Am. J. Hematol."},{"key":"34553_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.02.040","volume":"31","author":"LY Zhou","year":"2023","unstructured":"Zhou, L. Y. Research advance of BCR-ABL mutation and the efficacy of second and third generation TKI in chronic myeloid leukemia\u2013review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 31, 585\u2013588. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2023.02.040 (2023).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"34553_CR11","doi-asserted-by":"publisher","unstructured":"Sicuranza, A., Cavalleri, A. & Bernardi, S. The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers. Front. Oncol. 15 https:\/\/doi.org\/10.3389\/fonc.2025.1546813 (2025).","DOI":"10.3389\/fonc.2025.1546813"},{"key":"34553_CR12","doi-asserted-by":"crossref","unstructured":"Lv, L., Cui, H., Ma, Z., Liu, X. & Yang, L. Recent progresses in the Pharmacological activities of caffeic acid phenethyl ester. Naunyn-Schmiedeberg\u2019s Archives Pharmacology 394, 1327\u20131339, https:\/\/doi.org\/10.1007\/s00210-021-02054-w (2021 ).","DOI":"10.1007\/s00210-021-02054-w"},{"key":"34553_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/cancers14020274","volume":"14","author":"KS Chang","year":"2022","unstructured":"Chang, K. S. et al. The antitumor effect of caffeic acid phenethyl ester by downregulating mucosa-associated lymphoid tissue 1 via AR\/p53\/NF-\u03baB signaling in prostate carcinoma cells. Cancers 14, 274. https:\/\/doi.org\/10.3390\/cancers14020274 (2022).","journal-title":"Cancers"},{"key":"34553_CR14","doi-asserted-by":"publisher","unstructured":"Liang, Y. et al. Caffeic acid phenethyl ester suppressed growth and metastasis of nasopharyngeal carcinoma cells by inactivating the NF-\u03baB pathway. Drug. Des. Devel. Ther. 1335\u20131345. https:\/\/doi.org\/10.2147\/DDDT.S199182 (2019).","DOI":"10.2147\/DDDT.S199182"},{"key":"34553_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"34553_CR16","doi-asserted-by":"publisher","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44 https:\/\/doi.org\/10.1093\/nar\/gkv1070 (2016). D457-D462.","DOI":"10.1093\/nar\/gkv1070"},{"key":"34553_CR17","doi-asserted-by":"publisher","first-page":"8516","DOI":"10.1074\/jbc.M210432200","volume":"278","author":"N Li","year":"2003","unstructured":"Li, N. et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278, 8516\u20138525. https:\/\/doi.org\/10.1074\/jbc.M210432200 (2003).","journal-title":"J. Biol. Chem."},{"key":"34553_CR18","doi-asserted-by":"publisher","unstructured":"Murtaza, G. et al. Caffeic acid phenethyl ester and therapeutic potentials. BioMed research international 145342, (2014). https:\/\/doi.org\/10.1155\/2014\/145342 (2014).","DOI":"10.1155\/2014\/145342"},{"key":"34553_CR19","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/ijms20061468","volume":"20","author":"CC Cheng","year":"2019","unstructured":"Cheng, C. C. et al. Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the Inhibition of AKT\/ERK-dependent PDGF\/HIF-1\u03b1 in vitro and in vivo. Int. J. Mol. Sci. 20, 1468. https:\/\/doi.org\/10.3390\/ijms20061468 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"34553_CR20","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/molecules26051335","volume":"26","author":"B Olgierd","year":"2021","unstructured":"Olgierd, B., Kamila, \u017b., Anna, B. & Emilia, M. The pluripotent activities of caffeic acid phenethyl ester. Molecules 26, 1335. https:\/\/doi.org\/10.3390\/molecules26051335 (2021).","journal-title":"Molecules"},{"key":"34553_CR21","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.2174\/0109298673252993230921073502","volume":"31","author":"G Bj\u00f8rklund","year":"2024","unstructured":"Bj\u00f8rklund, G. et al. Caffeic acid phenethyl ester: A potential therapeutic cancer agent? Curr. Med. Chem. 31, 6760\u20136774. https:\/\/doi.org\/10.2174\/0109298673252993230921073502 (2024).","journal-title":"Curr. Med. Chem."},{"key":"34553_CR22","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/molecules22091554","volume":"22","author":"A Kaba\u0142a-Dzik","year":"2017","unstructured":"Kaba\u0142a-Dzik, A. et al. Comparison of two components of propolis: caffeic acid (CA) and caffeic acid phenethyl ester (CAPE) induce apoptosis and cell cycle arrest of breast cancer cells MDA-MB-231. Molecules 22, 1554. https:\/\/doi.org\/10.3390\/molecules22091554 (2017).","journal-title":"Molecules"},{"key":"34553_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/01635581.2013.776693","volume":"65","author":"S Akyol","year":"2013","unstructured":"Akyol, S. et al. In vivo and in vitro ant\u0131neoplastic actions of caffeic acid phenethyl ester (CAPE): therapeutic perspectives. Nutr. Cancer. 65, 515\u2013526. https:\/\/doi.org\/10.1080\/01635581.2013.776693 (2013).","journal-title":"Nutr. Cancer"},{"key":"34553_CR24","doi-asserted-by":"crossref","unstructured":"Lin, H. P. et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget 6, 6684, https:\/\/doi.org\/10.18632\/oncotarget.3246\u00a0(2015).","DOI":"10.18632\/oncotarget.3246"},{"key":"34553_CR25","doi-asserted-by":"crossref","unstructured":"Lin HuiPing, L. H. et al. Caffeic acid phenethyl ester as a potential treatment for advanced prostate cancer targeting Akt signaling. https:\/\/doi.org\/10.3390\/ijms14035264\u00a0(2013).","DOI":"10.3390\/ijms14035264"},{"key":"34553_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/01635581.2016.1153669","volume":"68","author":"TK Motawi","year":"2016","unstructured":"Motawi, T. K., Abdelazim, S. A., Darwish, H. A., Elbaz, E. M. & Shouman, S. A. Could caffeic acid phenethyl ester expand the antitumor effect of Tamoxifen in breast carcinoma? Nutr. Cancer. 68, 435\u2013445. https:\/\/doi.org\/10.1080\/01635581.2016.1153669 (2016).","journal-title":"Nutr. Cancer"},{"key":"34553_CR27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2174\/1570159X19666210608165509","volume":"19","author":"NP Kulkarni","year":"2021","unstructured":"Kulkarni, N. P., Vaidya, B., Narula, A. S. & Sharma, S. S. Neuroprotective potential of caffeic acid phenethyl ester (CAPE) in CNS disorders: mechanistic and therapeutic insights. Curr. Neuropharmacol. 19, 1401\u20131415. https:\/\/doi.org\/10.2174\/1570159X19666210608165509 (2021).","journal-title":"Curr. Neuropharmacol."},{"key":"34553_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cbdd.14233","volume":"102","author":"P Pandey","year":"2023","unstructured":"Pandey, P., Khan, F., Upadhyay, T. K. & Giri, P. P. Therapeutic efficacy of caffeic acid phenethyl ester in cancer therapy: an updated review. Chem. Biol. Drug Des. 102, 201\u2013216. https:\/\/doi.org\/10.1111\/cbdd.14233 (2023).","journal-title":"Chem. Biol. Drug Des."},{"key":"34553_CR29","doi-asserted-by":"publisher","first-page":"113951","DOI":"10.1016\/j.biopha.2022.113951","volume":"156","author":"C Guan","year":"2022","unstructured":"Guan, C., Zhou, X., Li, H., Ma, X. & Zhuang, J. NF-\u03baB inhibitors gifted by nature: the anticancer promise of polyphenol compounds. Biomed. Pharmacother. 156, 113951. https:\/\/doi.org\/10.1016\/j.biopha.2022.113951 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"34553_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep45465","volume":"7","author":"S Heinz","year":"2017","unstructured":"Heinz, S. et al. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of Pharmacological and safety evaluation. Sci. Rep. 7, 1\u201313. https:\/\/doi.org\/10.1038\/srep45465 (2017). www.sci-hub.se\/","journal-title":"Sci. Rep."},{"key":"34553_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller, J. H. Targeting transcription factors in cancer\u2014from undruggable to reality. Nat. Rev. Cancer. 19, 611\u2013624. https:\/\/doi.org\/10.1038\/s41568-019-0196-7 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"34553_CR32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","volume":"2","author":"C Bosc","year":"2021","unstructured":"Bosc, C. et al. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat. Cancer. 2, 1204\u20131223. https:\/\/doi.org\/10.1038\/s43018-021-00264-y (2021).","journal-title":"Nat. Cancer"},{"key":"34553_CR33","doi-asserted-by":"publisher","unstructured":"Pontis, F. et al. Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320. J. Experimental Clin. Cancer Res. 40 https:\/\/doi.org\/10.1186\/s13046-021-02040-3 (2021).","DOI":"10.1186\/s13046-021-02040-3"},{"key":"34553_CR34","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.redox.2020.101674","volume":"37","author":"D Nolfi-Donegan","year":"2020","unstructured":"Nolfi-Donegan, D., Braganza, A. & Shiva, S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 37, 101674. https:\/\/doi.org\/10.1016\/j.redox.2020.101674 (2020).","journal-title":"Redox Biol."},{"key":"34553_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 11, 102. https:\/\/doi.org\/10.1038\/s41467-019-13668-3 (2020).","journal-title":"Nat. Commun."},{"key":"34553_CR36","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1096\/fj.201801417R","volume":"33","author":"HA Kalpage","year":"2018","unstructured":"Kalpage, H. A. et al. Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis. FASEB J. 33, 1540. https:\/\/doi.org\/10.1096\/fj.201801417R (2018).","journal-title":"FASEB J."},{"key":"34553_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41420-022-00991-w","volume":"8","author":"Y Li","year":"2022","unstructured":"Li, Y., Zeng, P., Xiao, J., Huang, P. & Liu, P. Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy. Cell. Death Discovery. 8, 212. https:\/\/doi.org\/10.1038\/s41420-022-00991-w (2022).","journal-title":"Cell. Death Discovery"},{"key":"34553_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41419-023-05811-2","volume":"14","author":"L Feng","year":"2023","unstructured":"Feng, L. et al. BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP. Cell Death Dis. 14, 287. https:\/\/doi.org\/10.1038\/s41419-023-05811-2 (2023).","journal-title":"Cell Death Dis."},{"key":"34553_CR39","doi-asserted-by":"publisher","first-page":"862504","DOI":"10.3389\/fphar.2022.862504","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1. Front. Pharmacol. 13, 862504. https:\/\/doi.org\/10.3389\/fphar.2022.862504 (2022).","journal-title":"Front. Pharmacol."},{"key":"34553_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/14728214.2011.531698","volume":"16","author":"AC Burke","year":"2011","unstructured":"Burke, A. C., Swords, R. T., Kelly, K. & Giles, F. J. Current status of agents active against the T315I chronic myeloid leukemia phenotype. Expert Opin. Emerg. Drugs. 16, 85\u2013103. https:\/\/doi.org\/10.1517\/14728214.2011.531698 (2011).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"34553_CR41","doi-asserted-by":"publisher","first-page":"1183052","DOI":"10.3389\/fphar.2023.1183052","volume":"14","author":"C Gao","year":"2023","unstructured":"Gao, C. et al. I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL Inhibition. Front. Pharmacol. 14, 1183052. https:\/\/doi.org\/10.3389\/fphar.2023.1183052 (2023).","journal-title":"Front. Pharmacol."},{"key":"34553_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/eme03050","volume":"3","author":"EW Alton","year":"2016","unstructured":"Alton, E. W. et al. A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy Mechanism Evaluation. 3, 1\u2013210. https:\/\/doi.org\/10.3310\/eme03050 (2016).","journal-title":"Efficacy Mechanism Evaluation"},{"key":"34553_CR43","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-13-3044","volume":"20","author":"B S\u00e1nchez-S\u00e1nchez","year":"2014","unstructured":"S\u00e1nchez-S\u00e1nchez, B. et al. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res. 20, 4014\u20134025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3044 (2014).","journal-title":"Clin. Cancer Res."},{"key":"34553_CR44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/antiox13040461","volume":"13","author":"A Allegra","year":"2024","unstructured":"Allegra, A. et al. Oxidative stress and chronic myeloid leukemia: a balance between ROS-mediated pro-and anti-apoptotic effects of tyrosine kinase inhibitors. Antioxidants 13, 461. https:\/\/doi.org\/10.3390\/antiox13040461 (2024).","journal-title":"Antioxidants"},{"key":"34553_CR45","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cbin.70007","volume":"49","author":"A Cavalleri","year":"2025","unstructured":"Cavalleri, A. et al. Different in vitro models of chronic myeloid leukemia show different characteristics: biological replicates are not biologically equivalent. Cell. Biol. Int. 49, 570\u2013586. https:\/\/doi.org\/10.1002\/cbin.70007 (2025).","journal-title":"Cell. Biol. Int."},{"key":"34553_CR46","doi-asserted-by":"publisher","unstructured":"Mutti, S. et al. Assessment of chronic myeloid leukaemia in vitro models variability: insights into extracellular vesicles. J. Cell. Mol. Med. 29 https:\/\/doi.org\/10.1111\/jcmm.70901 (2025).","DOI":"10.1111\/jcmm.70901"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34553-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34553-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34553-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:24:02Z","timestamp":1769768642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34553-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34553"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34553-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was funded by the Shenzhen Association of Chinese Medicine (Grant No. 2024140\u00a0F) and the Futian Healthcare Research Project (Grant Nos. FTWS2022027, FTWS2022059, FTWS2023071).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}],"article-number":"4296"}}